A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Exclusion Criteria

• •Known untreated central nervous system metastases and/or carcinomatous meningitis
• •History of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.
• •Symptomatic ascites or pleural effusion.
• •Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
• •Active autoimmune disease that has required systemic treatment in past 2 years.
• •Has had an allogeneic tissue/solid organ transplant.
• •Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.
• •Has known history of or is positive for active Hepatitis B (HBsAg reactive) or has active Hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.
• •History or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's opinion, is clinically meaningful.
• •Use of protocol-defined prior/concomitant therapy.